GlassScriptPhysician profile
Taral J Doshi
NPI 1063677946
$2,026.54
in general payments reported to CMS, 2019-2025
22 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $227 · 2021: $708 · 2022: $141 · 2023: $139 · 2024: $167 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $487.75 | 2019-2021 | |
| Boston Scientific Corporation | $474.80 | 2019-2025 | General - Interventional Oncology |
| Stryker Corporation | $173.88 | 2020-2025 | Artix Mt |
| Penumbra, INC. | $143.87 | 2021 | |
| Becton, Dickinson and Company | $118.03 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $89.08 | 2019-2024 | Tagrisso |
| Inari Medical, INC. | $76.76 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cardiovascular Systems INC. | $75.12 | 2019 | |
| Cook Medical LLC | $70.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.81 | 2019-2020 | |
| Genentech USA, INC. | $49.35 | 2024 | Kadcyla, Phesgo, Perjeta |
| Medtronic, INC. | $28.99 | 2023 | Concertotm |
| Servier Pharmaceuticals LLC | $24.87 | 2024 | |
| Siemens Medical Solutions USA, INC. | $22.03 | 2022 | |
| Seagen INC. | $20.59 | 2023 | Tukysa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $19.88 | 2019 | |
| Puma Biotechnology, INC. | $19.60 | 2023 | |
| Incyte Corporation | $18.39 | 2023 | Jakafi |
| Agios Pharmaceuticals, INC. | $18.13 | 2023 | Pyrukynd |
| Argon Medical Devices, INC. | $16.78 | 2021 | |
| Janssen Biotech, INC. | $15.25 | 2023 | |
| Lilly USA, LLC | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taral Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.